Can Vaccinations Trigger or Exacerbate Chronic Urticaria? Authors: Young-Min Ye Published: 2024 Vaccination has been a cornerstone of public health since the introduction of the vaccinia virus vaccine in 1796.1 Most vaccines are well-tolerated, and their benefits significantly outweigh the risks of serious adverse reactions. Adverse events following immunization (AEFIs) are defined as any untoward medical occurrence that follows vaccination, regardless of whether a causal relationship has been established.2 Commonly reported AEFIs include cutaneous reactions, such as delayed urticaria, maculopapular rashes, or nonspecific eruptions. Local reactions are the most frequent AEFIs. Urticaria, the most common manifestation of anaphylaxis−a potentially life-threatening reaction−requires immediate diagnosis and management. Vaccine safety studies focus on monitoring urticaria that occurs immediately after vaccination. Although the incidence of acute urticaria as an AEFI ranges from 5%–13%, the risk of anaphylaxis after vaccinations has been estimated to be 1.31 per million doses.34 Vaccination against influenza, diphtheria-tetanus-pertussis (DTP), hepatitis B virus (HBV), hemophilus influenzae B, and meningococcus can induce acute urticaria.5 By contrast, chronic urticaria (CU), which characterized by recurrent itchy wheals and angioedema lasting > 6 weeks, has been underrecognized as a vaccine-related adverse event.6 A previous study reported that < 1% of CU patients developed urticarial symptoms within 12 weeks after vaccinations against HBV, influenza, yellow fever, or DTP.7 The widespread administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines during the coronavirus disease 2019 (COVID-19) pandemic has led to a significant rise in reported vaccine-associated adverse events, including CU. Similar to other vaccines, SARS-CoV-2 vaccines frequently cause mild, self-limiting side effects, including injection-site reactions, fatigue, headache, rash, fever, chills, muscle aches, and joint pain. However, there is a significant rise in reports of vaccine-associated CU following COVID-19 vaccinations. Multiple case series and retrospective studies have documented the potential of vaccines to induce, exacerbate, or trigger a relapse of CU.38910111213 Recent advances in understanding the pathogenesis of CU emphasize its complexity and heterogeneity. Although CU is driven primarily by mast cell activation, it is a chronic inflammatory disorder characterized by the infiltration of various immune cells, skewed cytokine profiles, upregulated vascular adhesion molecules, and enhanced neuroinflammation.14 The autoimmune mechanisms underlying CU involve type I autoallergy (immunoglobulin [Ig] E autoantibodies) and type IIb autoimmune reactions (IgG autoantibodies), which trigger mast cell activation and degranulation in affected individuals.15 Furthermore, several non-immunological factors, including complements, neuropeptides, and host defense peptides, have been implicated in influencing mast cell function.14 A comprehensive immune profiling study by a Chinese research group of patients with COVID-19 vaccine-induced CU revealed underlying thyroid disease, elevated levels of mast cell and T cell-mediated cytokines, autoreactive IgE/IgG antibodies against interleukin 24 and thyroid-related peptides, and anti-polyethylene glycol IgG.9 These findings imply a significant association between COVID-19 vaccine-induced autoimmunity and hyper-inflammation in the development of CU following vaccination. Consistent with these findings, patients whose CU relapsed within 12 weeks after COVID-19 vaccination exhibited higher rates of positive autologous serum skin tests, anti-nuclear antibodies, and basopenia.16 These markers are indicative of autoimmune CU. A multinational retrospective study of 2,769 COVID-19-vaccinated CU patients aged ≥ 18 years reported a 9% exacerbation rate, which occurred within 48 hours of vaccination and resolved within a few weeks.11 Identified risk factors for exacerbation included female sex, shorter urticaria duration (< 2 years), administration of adenovirus viral vector vaccine, intolerance to nonsteroidal anti-inflammatory drug, and vaccine anxiety.11 A previous study found that 14.3% of 105 CU patients, whose urticaria was well-controlled under omalizumab treatment experienced CU exacerbation following COVID-19 vaccination.13 Significant risk factors included symptomatic urticaria, even with mild pre-vaccination disease activity, and systemic reactogenicity with increased severity after vaccination. CU exacerbation was noted in less than half of the patients who experienced an exacerbation after their first COVID-19 vaccine dose.11 While common vaccine-related adverse reactions are well-characterized during clinical trials, rare events, particularly those with delayed onset or limited to specific subpopulations, are often identified through vaccine pharmacovigilance efforts. Globally, there are 2 primary pharmacovigilance databases: the Vaccine Adverse Event Reporting System, managed by the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration in the United States; and VigiBase, the World Health Organization international pharmacovigilance database which collects data from over 170 countries. Kang et al.17 analyzed the global reports of vaccine-associated CU submitted to VigiBase between 2010 and 2023, and identified a total of 1,898 vaccine-associated CU cases involving 27 different vaccines. Since the onset of the COVID-19 pandemic, there has been a significant 28-fold increase in reported CU cases compared to the 64 cases reported between 2010 and 2019. Notably, a disproportionality analysis revealed that COVID-19 mRNA vaccines had the highest reporting odds ratio at 26.52, followed by vaccines for papillomavirus (4.23), influenza (3.09), Ad5-vectored COVID-19 (2.82), and zoster (2.28). COVID-19 mRNA and Ad5-vectored vaccines demonstrated a higher likelihood of concurrent reports of dermatologic reactions and anaphylaxis, indicating a potential association with non-specific immune stimulation or allergic reactions.17 In addition, these vaccines were associated with an increased prevalence of neurologic reactions, at rates of 5.6% for mRNA vaccines and 8.2% for Ad-5 vectored vaccines, suggesting possible involvement of autoimmune mechanisms. Furthermore, previous studies have reported associations of papillomavirus and influenza vaccines with autoimmune conditions such as Guillain-Barré syndrome and vasculitis. Kang et al.17 observed that approximately 70% of the vaccine-associated CU reports in VigiBase involved females. However, their disproportionality analysis identified older age and male sex as risk factors for vaccine-associated CU. This study analyzed vaccine-associated CU using diagnostic codes from VigiBase, which does not distinguish between exacerbations, new-onset cases, or relapses. This limitation hinders accurate identification of risk factors and the underlying pathophysiology. Nevertheless, the clinical significance of this study lies in its identification of risks for vaccine-associated CU related to COVID-19, papillomavirus, influenza, and zoster vaccines. No fatalities have been reported in cases of vaccine-associated CU, and most instances have been successfully treated with antihistamines and omalizumab within a few months.317 Addressing these rare events is crucial for maintaining public trust in vaccines. Transparent communication about the risks and benefits of vaccines can help alleviate vaccine hesitancy. As our knowledge of the underlying mechanisms and risk factors for vaccine-induced CU expands, implementing targeted preventive measures for susceptible individuals before administering potentially problematic vaccines can minimize adverse outcomes.